[go: up one dir, main page]

NO976122L - AntiFasligandantistoffer og analysefremgangsmåte hvor disse anvendes - Google Patents

AntiFasligandantistoffer og analysefremgangsmåte hvor disse anvendes

Info

Publication number
NO976122L
NO976122L NO976122A NO976122A NO976122L NO 976122 L NO976122 L NO 976122L NO 976122 A NO976122 A NO 976122A NO 976122 A NO976122 A NO 976122A NO 976122 L NO976122 L NO 976122L
Authority
NO
Norway
Prior art keywords
assay method
ligand antibodies
phase ligand
phase
antibodies
Prior art date
Application number
NO976122A
Other languages
English (en)
Other versions
NO324120B1 (no
NO976122D0 (no
Inventor
Kamon Shirakawa
Tomokazu Matsusue
Shigekazu Nagata
Man Sung Co
Maximiliano Vasquez
Original Assignee
Mochida Pharm Co Ltd
Osaka Bioscience Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/649,100 external-priority patent/US6114507A/en
Application filed by Mochida Pharm Co Ltd, Osaka Bioscience Inst filed Critical Mochida Pharm Co Ltd
Publication of NO976122D0 publication Critical patent/NO976122D0/no
Publication of NO976122L publication Critical patent/NO976122L/no
Publication of NO324120B1 publication Critical patent/NO324120B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO19976122A 1995-06-30 1997-12-29 Anti-Fas-ligandantistoffer og analysefremgangsmate hvor disse anvendes, hybridomer som produserer antistoffene og preparat, reagens eller sett som omfatter antistoffene. NO324120B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP18848095 1995-06-30
US08/649,100 US6114507A (en) 1995-06-30 1996-05-17 Anti-Fas ligand antibody and assay method using the anti-Fas ligand antibody
PCT/JP1996/001820 WO1997002290A1 (en) 1995-06-30 1996-07-01 ANTIFas LIGAND ANTIBODIES AND ASSAY METHOD BY USING THE SAME

Publications (3)

Publication Number Publication Date
NO976122D0 NO976122D0 (no) 1997-12-29
NO976122L true NO976122L (no) 1998-02-27
NO324120B1 NO324120B1 (no) 2007-08-27

Family

ID=26504954

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19976122A NO324120B1 (no) 1995-06-30 1997-12-29 Anti-Fas-ligandantistoffer og analysefremgangsmate hvor disse anvendes, hybridomer som produserer antistoffene og preparat, reagens eller sett som omfatter antistoffene.

Country Status (8)

Country Link
EP (1) EP0842948B1 (no)
JP (1) JP3925663B2 (no)
CN (1) CN1196733A (no)
AU (1) AU724856B2 (no)
CA (1) CA2225852C (no)
NO (1) NO324120B1 (no)
NZ (1) NZ311174A (no)
WO (1) WO1997002290A1 (no)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998010070A1 (en) * 1996-09-02 1998-03-12 Sumitomo Electric Industries, Ltd. HUMANIZED IMMUNOGLOBULIN REACTING SPECIFICALLY WITH Fas LIGAND OR ACTIVE FRAGMENTS THEREOF AND REGION INDUCING APOPTOSIS ORIGINATING IN Fas LIGAND
US5858990A (en) * 1997-03-04 1999-01-12 St. Elizabeth's Medical Center Fas ligand compositions for treatment of proliferative disorders
US6972323B1 (en) 1997-04-01 2005-12-06 Sankyo Company, Limited Anti-Fas antibodies
US6204055B1 (en) * 1999-04-12 2001-03-20 Isis Pharmaceuticals, Inc. Antisense inhibition of Fas mediated signaling
CA2309598A1 (en) 1997-11-10 1999-05-20 Mochida Pharmaceutical Co., Ltd. Preventives and remedies for diffuse lung disease
EP1059089B1 (en) * 1998-02-06 2007-03-28 Mochida Pharmaceutical Co., Ltd. Preventives/remedies for inflammatory intestinal disease
WO1999058150A1 (en) * 1998-05-14 1999-11-18 Mochida Pharmaceutical Co., Ltd. Preventives/remedies for hepatic cirrhosis
ATE333287T1 (de) * 1998-05-29 2006-08-15 Mochida Pharm Co Ltd Prophylaxe und behandlung von autoimmunen entmyelinisierungserkrankungen durch fas- antagonisten
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
JP4734739B2 (ja) * 2000-09-29 2011-07-27 東レ株式会社 哺乳動物のガン抑制方法
EP1490405B1 (en) * 2002-03-21 2007-08-22 Eli Lilly And Company ANTAGONISTIC ANTI-hFAS LIGAND HUMAN ANTIBODIES AND FRAGMENTS THEREOF
WO2003086458A1 (en) * 2002-04-12 2003-10-23 Medimmune, Inc. Recombinant anti-interleukin-9 antibodies
TWI323265B (en) * 2002-08-06 2010-04-11 Glaxo Group Ltd Antibodies
BRPI0317376B8 (pt) * 2002-12-17 2021-05-25 Merck Patent Gmbh proteína de fusão de anticorpo-il2 designada como hu14.18-il2, usos da mesma, vetor e composição farmacêutica
EP1447093A1 (en) 2003-02-14 2004-08-18 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Inhibition of the CD95 ligand/receptor system for the treatment of neurological disorders and injuries
EP2316487B1 (en) * 2003-04-11 2014-06-11 MedImmune, LLC Recombinant IL-9 antibodies & uses thereof
CU23403A1 (es) * 2003-04-23 2009-08-04 Centro Inmunologia Molecular Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores
WO2005012363A1 (ja) * 2003-08-01 2005-02-10 Mochida Pharmaceutical Co., Ltd. 標的化された炎症惹起剤
US9309320B2 (en) 2006-12-28 2016-04-12 Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts Neutralization of CD95 activity blocks invasion of glioblastoma cells in vivo
HRP20150457T1 (hr) * 2007-12-12 2015-06-05 Pincell Srl Lijekovi protiv pemfigusa koji sadrže anti-fas lagand antitijela
US8540987B2 (en) 2008-01-29 2013-09-24 Institute For Antibodies Co., Ltd. Composition for neutralizing botulinus toxin type-A, and human anti-botulinus toxin type-A antibody
PT2376536E (pt) 2008-12-12 2015-05-11 Pincell Srl Remédios para pênfigo contendo anticorpos anti-ligando de faz
JP5754740B2 (ja) * 2009-07-21 2015-07-29 クイーン メアリー アンド ウェストフィールド カレッジＱｕｅｅｎ Ｍａｒｙ ａｎｄ Ｗｅｓｔｆｉｅｌｄ Ｃｏｌｌｅｇｅ 細胞内薬物送達のためのｆａｓ（アポ−１，ｃｄ９５）標的化プラットフォーム
JO3437B1 (ar) 2009-10-30 2019-10-20 Esai R & D Man Co Ltd أجسام مضادة محسنة مضادة للفراكتالكين البشري واستخداماتها
DK3140653T3 (da) 2014-05-08 2022-06-20 Novodiax Inc Direkte immunhistokemianalyse
EP3076179A1 (en) 2015-03-30 2016-10-05 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Diagnosis and treatment of low grade gliomas
AU2016325482B2 (en) * 2015-09-23 2020-09-03 Apogenix Ag Anti-CD95L antibody
PL3592392T3 (pl) * 2017-03-10 2024-03-18 University Of Louisville Research Foundation, Inc. Biomateriały modyfikowane fasl o funkcji immunomodulacyjnej
WO2023138521A1 (zh) * 2022-01-21 2023-07-27 北京三诺佳邑生物技术有限责任公司 特异性识别FasL的抗体及其应用
US20250257141A1 (en) 2022-04-26 2025-08-14 Hoffmann-La Roche Inc. Combination therapy for the treatment of cancer comprising a fas axis antagonist and a t-reg cell depleting agent antagonist

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU665190B2 (en) 1990-07-10 1995-12-21 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
AU705114B2 (en) * 1993-10-14 1999-05-13 Immunex Corporation Fas antagonists and uses thereof
JPH08127594A (ja) 1993-11-10 1996-05-21 Mochida Pharmaceut Co Ltd Ｆａｓ抗原に結合する新規蛋白質およびそれをコードするＤＮＡ
AU705484B2 (en) * 1994-01-07 1999-05-20 Mochida Pharmaceutical Co., Ltd. Ligand that binds fas antigen
EP0872488B1 (en) 1995-03-20 2006-05-24 Ko Okumura MONOCLONAL ANTIBODY REACTING SPECIFICALLY WITH Fas LIGAND AND PROCESS FOR PRODUCING THE SAME

Also Published As

Publication number Publication date
CN1196733A (zh) 1998-10-21
NZ311174A (en) 1999-04-29
WO1997002290A1 (en) 1997-01-23
EP0842948A4 (en) 2004-12-15
EP0842948A1 (en) 1998-05-20
NO324120B1 (no) 2007-08-27
AU724856B2 (en) 2000-10-05
JP3925663B2 (ja) 2007-06-06
AU6243596A (en) 1997-02-05
CA2225852C (en) 2009-04-14
NO976122D0 (no) 1997-12-29
EP0842948B1 (en) 2009-04-22
CA2225852A1 (en) 1997-01-23

Similar Documents

Publication Publication Date Title
NO976122L (no) AntiFasligandantistoffer og analysefremgangsmåte hvor disse anvendes
NO996551D0 (no) Forbedrete anti-IgE-antistoffer og fremgangsmåte for forbedring av polypeptider
ID19197A (id) Pesawat pengolah informasi dan metode pengolah informasi
DE69632366D1 (de) Probenfördereinrichtung
DK0825946T3 (da) Fremgangsmåde til lastning og behandling af hydrocarboner
NO962346D0 (no) Humaniserte antistoffer og anvendelser derav
FI101829B1 (fi) Biospesifinen määritysmenetelmä
DE69638207D1 (de) Prozessor und Verarbeitungsverfahren für Dokumente
DE69428749D1 (de) Analyt-nachweis Gerät und Verfahren
DE69427123D1 (de) Screeningverfahren für katalytische nicht-enzym-polypeptide und-proteine
FI950507A7 (fi) Määritysmenetelmä proteiinin määrittämiseksi biologisesta näytteestä
FI923025L (fi) Diagnostinen menetelmä synnytysajankohdan ennustamiseksi sekä siihen käytettävä reagenssipakkaus
FI954499L (fi) Menetelmä ja analyysi
DE69608277D1 (de) Probenanalysegerät
EP0699909A3 (en) Method for the determination of fibrinogen and reagent for its determination
FI931735A7 (fi) Menetelmä ei-spesifisten reaktioiden eliminoimiseksi immunoanalyysissä
DE69526875D1 (de) Suppressor von nichtspezifischen Reaktionen in Immuno-Assays
KR970703146A (ko) 류마티스성 관절염의 치료방법 및 시약(method and reagents for the treatment of rheumatoid arthritis)
EP1079231A4 (en) Immunoassay reagents and immunoassay method
EP0831935A4 (en) GASEOUS ULTRASONIC CONTRAST AGENTS AND RELATED METHODS
FI964604L (fi) Menetelmä ja reagensseja nivelreuman hoitamiseksi
DK0780388T3 (da) 5HT1Dalfa og 5HT2A ligander
DE69426354D1 (de) Reagenz zur bestimmung von glucose
ZA944024B (en) Immunoassay reagents and methods for detecting brequinar and analoges
FI954948L (fi) Putkiliitos sekä menetelmä sen käyttämiseksi